4-aminobenzoic acid has been researched along with Pulmonary Disease, Chronic Obstructive in 6 studies
para-Aminobenzoates: Benzoic acids, salts, or esters that contain an amino group attached to carbon number 4 of the benzene ring structure.
4-aminobenzoate : An aromatic amino-acid anion that is the conjugate base of 4-aminobenzoic acid.
Pulmonary Disease, Chronic Obstructive: A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We aimed to characterise the whole genome gene expression profile of the inhaled PDE4-inhibitor CHF6001 on top of triple therapy in sputum cells and whole blood of patients with COPD and chronic bronchitis." | 9.34 | Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis. ( Afolabi, EK; Bassi, M; Beeh, KM; Colgan, B; Emirova, A; Govoni, M; Jellema, GL; Kornmann, O; Leaker, B; Lucci, G; Nandeuil, MA; Petruzzelli, S; Singh, D; Vezzoli, S; Watz, H, 2020) |
| "CHF6001 is a novel inhaled phosphodiesterase-4 inhibitor." | 6.90 | Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD. ( Beeh, KM; Colgan, B; Emirova, A; Geraci, S; Govoni, M; Kornmann, O; Leaker, B; Lucci, G; Nandeuil, MA; Singh, D; Watz, H, 2019) |
| " We aimed to characterise the whole genome gene expression profile of the inhaled PDE4-inhibitor CHF6001 on top of triple therapy in sputum cells and whole blood of patients with COPD and chronic bronchitis." | 5.34 | Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis. ( Afolabi, EK; Bassi, M; Beeh, KM; Colgan, B; Emirova, A; Govoni, M; Jellema, GL; Kornmann, O; Leaker, B; Lucci, G; Nandeuil, MA; Petruzzelli, S; Singh, D; Vezzoli, S; Watz, H, 2020) |
| "CHF6001 had no effect in the primary lung function analysis, although was well-tolerated with no gastrointestinal adverse event signal." | 2.94 | Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study. ( Emirova, A; Francisco, C; Govoni, M; Nandeuil, MA; Santoro, D; Singh, D, 2020) |
| "CHF6001 is a novel inhaled phosphodiesterase-4 inhibitor." | 2.90 | Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD. ( Beeh, KM; Colgan, B; Emirova, A; Geraci, S; Govoni, M; Kornmann, O; Leaker, B; Lucci, G; Nandeuil, MA; Singh, D; Watz, H, 2019) |
| "CHF6001 is an inhaled PDE4 inhibitor, while inhaled ensifentrine is an inhibitor of both PDE3 and PDE4; antagonism of PDE3 facilitates smooth muscle relaxation and hence bronchodilation." | 2.72 | Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease. ( Lea, S; Mathioudakis, AG; Singh, D, 2021) |
| "AM from 13 chronic obstructive pulmonary disease (COPD) patients and 10 smoking controls and lung tissue from 7 COPD patients were stimulated with LPS following preincubation with roflumilast (0." | 1.51 | The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients. ( Bridgewood, C; Civelli, M; Facchinetti, F; Higham, A; Lea, S; Li, J; Metryka, A; Singh, D; Villetti, G, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 4 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Singh, D | 5 |
| Lea, S | 2 |
| Mathioudakis, AG | 1 |
| Schioppa, T | 1 |
| Nguyen, HO | 1 |
| Salvi, V | 1 |
| Maugeri, N | 1 |
| Facchinetti, F | 2 |
| Villetti, G | 2 |
| Civelli, M | 2 |
| Gaudenzi, C | 1 |
| Passari, M | 1 |
| Sozio, F | 1 |
| Barbazza, I | 1 |
| Tamassia, N | 1 |
| Cassatella, MA | 1 |
| Del Prete, A | 1 |
| Bosisio, D | 1 |
| Tiberio, L | 1 |
| Beeh, KM | 2 |
| Colgan, B | 2 |
| Kornmann, O | 2 |
| Leaker, B | 2 |
| Watz, H | 2 |
| Lucci, G | 2 |
| Geraci, S | 1 |
| Emirova, A | 3 |
| Govoni, M | 3 |
| Nandeuil, MA | 3 |
| Bassi, M | 1 |
| Vezzoli, S | 1 |
| Petruzzelli, S | 1 |
| Jellema, GL | 1 |
| Afolabi, EK | 1 |
| Francisco, C | 1 |
| Santoro, D | 1 |
| Metryka, A | 1 |
| Li, J | 1 |
| Higham, A | 1 |
| Bridgewood, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Double-blind,Placebo Controlled, Repeated Dose, Three-way Crossover Study to Evaluate the Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPD[NCT03004417] | Phase 2 | 61 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| A 24-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active Controlled, Parallel Group, Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of CHF6001 DPI in Patients With COPD on a Background Therapy[NCT02986321] | Phase 2 | 1,130 participants (Actual) | Interventional | 2016-12-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for 4-aminobenzoic acid and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease.
Topics: Administration, Inhalation; Aminopyridines; Animals; Benzamides; Cyclic AMP; Cyclopropanes; Humans; | 2021 |
3 trials available for 4-aminobenzoic acid and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD.
Topics: Aged; Biomarkers; Bronchodilator Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doubl | 2019 |
Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis.
Topics: Administration, Inhalation; Aged; Anti-Inflammatory Agents; Biomarkers; Bronchitis, Chronic; Cross-O | 2020 |
Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study.
Topics: Administration, Inhalation; Adult; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Ma | 2020 |
2 other studies available for 4-aminobenzoic acid and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
The PDE4 Inhibitor Tanimilast Restrains the Tissue-Damaging Properties of Human Neutrophils.
Topics: Cytokines; Endothelial Cells; Extracellular Traps; Humans; Neutrophils; para-Aminobenzoates; Phospho | 2022 |
The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Benzamides; Chemokine CCL2; Chemokine CCL4; Cyclopro | 2019 |